PhaseBio Pharmaceuticals (PHAS) Issues Earnings Results

PhaseBio Pharmaceuticals (NASDAQ:PHAS) posted its quarterly earnings data on Thursday. The company reported ($10.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($10.23), Fidelity Earnings reports. The business had revenue of $0.41 million during the quarter.

Shares of PHAS opened at $2.85 on Friday. PhaseBio Pharmaceuticals has a 52-week low of $2.55 and a 52-week high of $6.00.

A number of equities analysts have commented on the company. Needham & Company LLC assumed coverage on PhaseBio Pharmaceuticals in a research note on Tuesday, November 13th. They set a “buy” rating and a $18.00 price objective on the stock. Stifel Nicolaus assumed coverage on PhaseBio Pharmaceuticals in a research note on Monday, November 12th. They set a “buy” rating and a $14.00 price objective on the stock. Citigroup assumed coverage on PhaseBio Pharmaceuticals in a research note on Monday, November 12th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, Cowen assumed coverage on PhaseBio Pharmaceuticals in a research note on Monday, November 12th. They set an “outperform” rating on the stock.



In other PhaseBio Pharmaceuticals news, major shareholder Venture Advisors Iii Hatteras purchased 300,000 shares of the firm’s stock in a transaction dated Monday, October 22nd. The shares were bought at an average price of $5.00 per share, for a total transaction of $1,500,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Linda Tufts purchased 20,000 shares of the firm’s stock in a transaction dated Monday, October 22nd. The stock was acquired at an average price of $5.00 per share, for a total transaction of $100,000.00. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY NOTICE: “PhaseBio Pharmaceuticals (PHAS) Issues Earnings Results” was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://dakotafinancialnews.com/2018/12/01/phasebio-pharmaceuticals-phas-issues-earnings-results.html.

PhaseBio Pharmaceuticals Company Profile

PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.

Further Reading: What are the reasons investors use put options?

Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply